ATRECA

atreca-logo

Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.

#SimilarOrganizations #People #Financial #Event #Website #More

ATRECA

Social Links:

Industry:
Biotechnology Health Care Product Research Therapeutics

Founded:
2010-01-01

Address:
San Carlos, California, United States

Country:
United States

Website Url:
http://www.atreca.com

Total Employee:
51+

Status:
Active

Contact:
6505952618

Email Addresses:
[email protected]

Total Funding:
347.86 M USD

Technology used in webpage:
Google Maps IPv6 ReCAPTCHA ReCAPTCHA V2 Akamai Hosted Energy Group Hosting


Similar Organizations

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

Current Employees Featured

wayne-volkmuth_image

Wayne Volkmuth
Wayne Volkmuth SVP Informatics and IT, Co-founder @ Atreca
SVP Informatics and IT, Co-founder

jonathan-woo_image

Jonathan Woo
Jonathan Woo Senior Vice President, Finance & Strategy, Co-Founder @ Atreca
Senior Vice President, Finance & Strategy, Co-Founder

daniel-emerling_image

Daniel Emerling
Daniel Emerling Consultant and Founder @ Atreca
Consultant and Founder
2022-10-01

john-a-orwin_image

John A Orwin
John A Orwin President and CEO @ Atreca
President and CEO
2018-04-01

christopher-murriel_image

Christopher Murriel
Christopher Murriel Director, In Vivo Pharmacology @ Atreca
Director, In Vivo Pharmacology
2020-03-01

stephen-gould_image

Stephen Gould
Stephen Gould Chief Scientific Officer @ Atreca
Chief Scientific Officer
2022-06-01

herb-c-cross_image

Herb C. Cross
Herb C. Cross Chief Financial Officer @ Atreca
Chief Financial Officer
2019-04-01

tito-a-serafini_image

Tito A Serafini
Tito A Serafini Chief Strategy Officer, Director, & Founder @ Atreca
Chief Strategy Officer, Director, & Founder
2018-04-01

philippe-bishop_image

Philippe Bishop
Philippe Bishop Chief Medical Officer @ Atreca
Chief Medical Officer
2023-01-01

Founder


daniel-emerling_image

Daniel Emerling

guy-cavet_image

Guy Cavet

jonathan-woo_image

Jonathan Woo

paulette-dillon_image

Paulette Dillon

tito-a-serafini_image

Tito A Serafini

wayne-volkmuth_image

Wayne Volkmuth

yann-chong-tan_image

Yann Chong Tan

Stock Details


Company's stock symbol is NASDAQ:BCEL

Investors List

wellington-management_image

Wellington Management

Wellington Management investment in Series C - Atreca

samsara-biocapital_image

Samsara BioCapital

Samsara BioCapital investment in Series C - Atreca

tavistock-life-sciences_image

Tavistock Life Sciences

Tavistock Life Sciences investment in Series C - Atreca

redmile-group_image

Redmile Group

Redmile Group investment in Series C - Atreca

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series C - Atreca

boxer-capital_image

Boxer Capital

Boxer Capital investment in Series C - Atreca

aisling-capital_image

Aisling Capital

Aisling Capital investment in Series C - Atreca

ecor1-capital_image

EcoR1 Capital

EcoR1 Capital investment in Series C - Atreca

tekla-capital-management_image

Tekla Capital Management

Tekla Capital Management investment in Series C - Atreca

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series B - Atreca

Official Site Inspections

http://www.atreca.com Semrush global rank: 3.9 M Semrush visits lastest month: 2.91 K

  • Host name: 23.163.196.104.bc.googleusercontent.com
  • IP address: 104.196.163.23
  • Location: United States
  • Latitude: 38.6583
  • Longitude: -77.2481
  • Timezone: America/New_York

Loading ...

More informations about "Atreca"

Atreca - Crunchbase Company Profile & Funding

Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. View contacts for Atreca to access new leads and connect with decision-makers.See details»

Atreca, Inc. - LinkedIn

Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer โ€ฆSee details»

Atreca, Inc. - AnnualReports.com

Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform.See details»

Atreca Company Profile - Office Locations, Competitors, Revenue โ€ฆ

Jun 14, 2024 Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer โ€ฆSee details»

Atreca Announces Asset Purchase Agreement for Sale of Antibody โ€ฆ

Dec 26, 2023 Atreca, Inc. CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (โ€œAtrecaโ€) (NASDAQ: BCEL), a biotechnology company focused on developing novel โ€ฆSee details»

Atreca - BIO International Convention | BIO

Jun 5, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Atrecaโ€™s โ€ฆSee details»

Atreca - Contacts, Employees, Board Members, Advisors & Alumni

Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. ... Products. Resources. Pricing. Resources. โ€ฆSee details»

Atreca Announces Corporate Reorganization to Extend Cash Runway

Jun 1, 2022 Company continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets Extends cash runway through 2023 and reduces workforce by more than 25% On track โ€ฆSee details»

Atreca - Bill & Melinda Gates Foundation

Atrecaโ€™s proprietary discovery platform generates and develops therapeutics based on rapid characterization of human adaptive immune response at the single cell level. Foundation โ€ฆSee details»

Atreca Enters into Licensing Agreement with Bill & Melinda Gates ...

SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics โ€ฆSee details»

Biotech company Atreca is winding down, but its antimalarial drug โ€ฆ

Jan 29, 2024 For Atreca to find a malaria-focused antibody, it had to score highly on World Health Organization guidelines for ease of manufacturing, a low cost of goods and viscosity โ€” โ€ฆSee details»

Atreca, Inc., Completes Oversubscribed $56 Million ... - Fierce Biotech

Nov 5, 2015 Dr. William Robinson, Atreca Co-Founder and Board member, commented, "Atreca's technology has the potential to create a broad proprietary position within the immuno โ€ฆSee details»

Atreca Reports Third Quarter 2023 Financial Results and ... - Nasdaq

Nov 14, 2023 About Atreca, Inc. Atreca is a biopharmaceutical company developing novel antibody-based therapeutics generated by its differentiated discovery platform, with a focus on โ€ฆSee details»

Atreca downsizes again to focus on antibody-drug conjugate โ€ฆ

Nov 15, 2023 Atreca expects to file an investigational new drug (IND) application with the US Food and Drug Administration (FDA) in late 2024 or early 2025, as per a 10 August press โ€ฆSee details»

Atreca Announces Corporate Reorganization to Extend Cash โ€ฆ

SAN CARLOS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics โ€ฆSee details»

Atreca Announces Strategic Research Collaboration with

May 2, 2020 Under the terms of the agreement, Atreca will receive an upfront cash payment and retain exclusive ownership and rights to develop all Atreca antibodies included in the โ€ฆSee details»

Atreca Announces Expansion of Preclinical Pipeline - GlobeNewswire

Apr 5, 2022 Atreca Announces Licensing Agreement with Zymeworks. Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate. Virtual R&D Day scheduled for today at โ€ฆSee details»

Atreca Reports Third Quarter 2021 Financial Results and Recent ...

Nov 2, 2021 Atreca announced a licensing agreement with the Bill & Melinda Gates Medical Research Institute (โ€œGates MRIโ€) for development and commercialization of MAM01/ATRC โ€ฆSee details»

Atreca Is A Unique Biotech With Key Data Readouts In Coming Years

Nov 12, 2021 Atreca Inc. is a good speculative biotech to look into. It reported some good initial data with ATRC-101 being able to help 8 out of 20 advanced solid tumor patients achieve โ€ฆSee details»

Atreca (BCEL) Locks In A Catalyst In The Oncology Space

Feb 1, 2023 Atreca is a biotechnology company with a upcoming catalyst from its lead pipeline candidate, ATRC-101, in advanced solid malignancies.This article takes a look at the data to โ€ฆSee details»

linkstock.net © 2022. All rights reserved